Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.
Intranasal delivery of vaccines directed against respiratory pathogens is an attractive alternative to parenteral administration. However, using this delivery route for inactivated vaccines usually requires the use of potent mucosal adjuvants, and no such adjuvant has yet been approved for human use...
Main Authors: | Hana Kammoun, Xavier Roux, Dominique Raze, Anne-Sophie Debrie, Marina De Filette, Tine Ysenbaert, Nathalie Mielcarek, Xavier Saelens, Walter Fiers, Camille Locht |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3602086?pdf=render |
Similar Items
-
Manufacture of a Stable Lyophilized Formulation of the Live Attenuated Pertussis Vaccine BPZE1
by: Marcel Thalen, et al.
Published: (2020-09-01) -
Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
by: Nathalie Mielcarek, et al.
Published: (2006-07-01) -
The Role of Mucosal Immunity in Pertussis
by: Luis Solans, et al.
Published: (2019-01-01) -
The History of Pertussis Toxin
by: Camille Locht, et al.
Published: (2021-09-01) -
Suppression of mucosal Th17 memory responses by acellular pertussis vaccines enhances nasal Bordetella pertussis carriage
by: Violaine Dubois, et al.
Published: (2021-01-01)